Bionova Capital
Bionova Capital is a healthcare-focused venture capital firm based in Lisbon, Portugal, established in 2015. It invests in seed and early-stage life science companies across Europe, with a focus on therapeutics, biotechnology, digital health, medical devices and related health technology. The firm typically makes minority investments of roughly €200,000 to €1,000,000 per project, supporting startups through early growth and scale. It is formed by shareholders of Hovione, a large Portuguese pharmaceutical company, linking Bionova Capital to a broader pharmaceutical and research background, though it operates as an independent investment firm. The approach emphasizes backing innovative ventures in Europe that aim to advance drugs, diagnostics and health tech from concept to market.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Portugal
Delox
Seed Round in 2022
Delox designs and develops bio-decontamination devices and automatic decontamination robots that use a solid hydrogen peroxide formulation to deliver rapid, safe disinfection and maintain sterile conditions in healthcare, laboratory and industrial environments. Originating as a spin-off from the University of Lisbon's Faculty of Sciences, the company focuses on compact, cost-effective solutions such as the Delox Box, supported by DeloxHP cartridges that store and release concentrated hydrogen peroxide vapor. Its products enable sterilization of medical devices in hospitals, room decontamination in medical facilities, pharma and food industries, as well as decontamination of laboratory equipment and environmental test chambers. Founded in 2018 and based in Cascais, Portugal, Delox targets facilities that require non-toxic, efficient bio-decontamination to preserve biosafety and reduce downtime.
CellmAbs
Seed Round in 2019
CellmAbs, established in 2019 and headquartered in Lisbon, Portugal, specializes in developing therapies for glycoimmunology and oncology. As a spin-off from NOVA University of Lisbon, the company focuses on creating solutions for cancer treatment, immunotherapies, and glycobiology. CellmAbs has swiftly grown into an internationally experienced team, having produced several preclinical candidates targeting solid tumors by leveraging advanced knowledge of cancer-specific glycan targets.
CellmAbs
Seed Round in 2019
CellmAbs, established in 2019 and headquartered in Lisbon, Portugal, specializes in developing therapies for glycoimmunology and oncology. As a spin-off from NOVA University of Lisbon, the company focuses on creating solutions for cancer treatment, immunotherapies, and glycobiology. CellmAbs has swiftly grown into an internationally experienced team, having produced several preclinical candidates targeting solid tumors by leveraging advanced knowledge of cancer-specific glycan targets.
Delox
Seed Round in 2018
Delox designs and develops bio-decontamination devices and automatic decontamination robots that use a solid hydrogen peroxide formulation to deliver rapid, safe disinfection and maintain sterile conditions in healthcare, laboratory and industrial environments. Originating as a spin-off from the University of Lisbon's Faculty of Sciences, the company focuses on compact, cost-effective solutions such as the Delox Box, supported by DeloxHP cartridges that store and release concentrated hydrogen peroxide vapor. Its products enable sterilization of medical devices in hospitals, room decontamination in medical facilities, pharma and food industries, as well as decontamination of laboratory equipment and environmental test chambers. Founded in 2018 and based in Cascais, Portugal, Delox targets facilities that require non-toxic, efficient bio-decontamination to preserve biosafety and reduce downtime.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.